Theripion v. Vidal: Federal Circuit Vacates ApoA-1 Fusion Polypeptide Ruling
Theripion, Inc. appealed a USPTO patentability determination covering ApoA-1 fusion polypeptide compositions and methods (Application No. US15/909314) to the Federal Circuit. After 580 days, the court vacated the lower decision and remanded the matter for further proceedings.
Federal Circuit nullifies USPTO's ApoA-1 patentability determination
Theripion, Inc. filed this appeal at the Court of Appeals for the Federal Circuit on 7 January 2022, challenging a USPTO patentability determination relating to patent application US15/909314, which covers ApoA-1 fusion polypeptide compositions and related methods. The named defendants are USPTO Director Katherine K. Vidal and Acting Director Andrew Hirshfeld, represented by USPTO solicitors. Theripion was represented by counsel from Greenblum & Bernstein, PLC.
The case closed on 10 August 2023. The recorded basis of termination is 'Vacated and Remanded'; the docket order states: 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: VACATED AND REMANDED.' The Federal Circuit did not affirm the USPTO's underlying patentability ruling — instead it nullified that decision and returned the matter to the agency or lower tribunal for further consideration.
See Complete Case & Patent Analysis →Filing to Vacated and Remanded in 580 days
580 days from filing to Federal Circuit disposition
US15/909314 — ApoA-1 fusion polypeptide compositions and methods
Any R&D team or product organisation developing ApoA-1 fusion proteins, apolipoprotein-based drug delivery platforms, or HDL-mimetic therapeutics should treat this application as a live FTO risk. The Federal Circuit's vacatur means the USPTO's prior adverse determination is gone — the application may yet issue with enforceable claims. Until remanded proceedings conclude, the claim scope remains uncertain.
Official order — verbatim text
The Federal Circuit's order — 'VACATED AND REMANDED' — nullifies the USPTO's prior patentability determination on application US15/909314 and returns the matter for further proceedings. A vacatur at this appellate level signals the court identified reversible error or an inadequate basis in the agency's reasoning; the specific grounds are not detailed in the available record.
Federal Circuit vacates: what the ruling means for both parties
What 'Vacated and Remanded' means at the appellate level
A vacatur nullifies the lower decision — it is as if the prior ruling never stood. The Federal Circuit found sufficient grounds to set aside the USPTO's patentability determination without substituting its own final judgment. Remand returns the matter to the originating tribunal or agency for proceedings consistent with the appellate court's guidance. The specific grounds for vacatur are not disclosed in the available record.
Lower decision nullifiedTheripion gets a second opportunity on patentability
For Theripion, vacatur is a procedurally significant win: the adverse patentability determination no longer stands. The application US15/909314 returns to further examination or review proceedings. Whether this ultimately yields an issued patent depends on how the remanded proceedings resolve — the Federal Circuit's vacatur does not guarantee allowance.
Patentability decision resetAgency must reconsider its patentability analysis
The USPTO's prior determination has been set aside. The agency — represented by Director Vidal and former Acting Director Hirshfeld — will need to re-examine the issues identified by the Federal Circuit on remand. The specific errors or deficiencies that prompted vacatur are not detailed in the available public record.
Agency determination set asideApoA-1 fusion polypeptide space remains contested
Until remanded proceedings conclude and a new patentability determination is issued, freedom-to-operate assessments in the ApoA-1 fusion polypeptide space should account for the reinstated uncertainty around this application. Companies active in apolipoprotein-based therapeutics and fusion protein compositions should monitor the outcome of the remanded proceedings closely.
Monitor remand outcomeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Theripion, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Katherine K. Vidal | Individual | /Search in Eureka ↗ |
| Co-Defendant | Andrew Hirshfeld | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Jill Browning | Attorney | Counsel for Theripion, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicholas V. Sherbina | Attorney | Counsel for Theripion, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Greenblum & Bernstein, PLC | Law Firm | Representing Theripion, Inc.Search in Eureka ↗ |
| Defendant counsel | Amy J. Nelson | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Farheena Yasmeen Rasheed Deputy Solicitor | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Mary L. Kelly | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Robert Mcbride Associate Solicitor | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Defendant counsel | Thomas W. Krause | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the ApoA-1 fusion polypeptide space
Forward-looking patent and R&D intelligence derived from Theripion v. Vidal — tracking innovation activity around ApoA-1 fusion proteins and apolipoprotein-based therapeutics.
Theripion's ApoA-1 filing activity beyond US15/909314
Theripion's pursuit of this application to the Federal Circuit suggests genuine commercial intent to protect ApoA-1 fusion polypeptide technology. Mapping their broader portfolio — including continuations, divisionals, and PCT equivalents — can reveal the full scope of claimed subject matter and identify where their IP perimeter may expand after remand.
Theripion portfolioFiling trends in ApoA-1 and apolipoprotein fusion therapeutics
ApoA-1 fusion protein technology sits at the intersection of cardiovascular biology, protein engineering, and targeted drug delivery. Tracking recent filings in this domain can surface emerging assignees, novel fusion architectures, and indication expansions — particularly relevant as Theripion's claims remain pending on remand.
ApoA-1 filing trendsUSPTO and competitor positions in HDL-mimetic protein patents
The USPTO's decision to contest this application through solicitor-level representation suggests the patentability question has policy relevance. Competitor organisations engineering HDL-mimetic or ApoA-1-conjugate biologics should assess how the remanded examination and any resulting claims could interact with their own pipeline assets.
HDL-mimetic IP riskAdjacent claim space near ApoA-1 fusion polypeptide compositions
With Theripion's application in flux post-vacatur, adjacent technical areas — such as ApoA-1 variants with different fusion partners, delivery formulations, or non-cardiovascular indications — may represent white-space filing opportunities. A landscape search can identify where current patent density is low relative to biological activity.
Fusion protein white spaceSimilar Federal Circuit patentability appeals in biopharmaceuticals
Cases involving Federal Circuit appeals of USPTO patentability determinations in the biologics and fusion protein space, heard in the District of Columbia circuit.
What this case signals for the biopharmaceutical patent landscape
A Federal Circuit vacatur in a USPTO patentability appeal is a relatively high-stakes signal for applicants and competitors in the biologics space.
Vacatur resets the patentability clock for ApoA-1 fusion technology
Theripion's application remains live and contested. Any competitor designing around or relying on the absence of this patent should revisit their FTO position — the remanded proceedings could result in claims issuing in amended or original form.
USPTO solicitor-level defence suggests systemic examination issues were at stake
The USPTO deployed multiple solicitors including the Deputy Solicitor and Associate Solicitor to defend this appeal, suggesting the patentability question engaged examination policy or precedent, not merely fact-specific error. The specific issue is not disclosed in the available record.
Theripion v Katherine — key questions answered
The Federal Circuit vacated the USPTO's patentability determination concerning application US15/909314 (ApoA-1 fusion polypeptides) and remanded the matter for further proceedings. The case closed on 10 August 2023, approximately 580 days after filing. The specific grounds for vacatur are not detailed in the available public record.
Vacatur nullifies the prior USPTO ruling — it no longer stands as a binding determination. Remand returns the matter to the agency or lower tribunal for further proceedings consistent with the Federal Circuit's order. For Theripion, this means the adverse patentability finding has been set aside and the application remains live, though allowance is not guaranteed.
Application US15/909314, published as US20180201664A1, covers ApoA-1 fusion polypeptides and related compositions and methods. ApoA-1 is the principal protein of high-density lipoprotein (HDL), and fusion polypeptide strategies in this area are relevant to cardiovascular, anti-inflammatory, and targeted drug-delivery applications.
The named defendants were Katherine K. Vidal, Director of the USPTO, and Andrew Hirshfeld, former Acting Director of the USPTO. They were represented by multiple USPTO solicitors including the Deputy Solicitor and Associate Solicitor, indicating the agency mounted a substantive institutional defence of the patentability determination.
The vacatur means the prior adverse patentability ruling is gone and application US15/909314 remains pending on remand. Companies developing ApoA-1 fusion proteins or apolipoprotein-based therapeutics should not rely on the USPTO's prior determination as clearing their FTO path. The application may yet issue with enforceable claims, and the claim scope remains uncertain until remanded proceedings conclude.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.